Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte Sees Higher Interim Revenue, Confident On Long-Term Prospects

Wed, 15th Jul 2020 13:31

(Alliance News) - MaxCyte Inc on Wednesday predicted a sharp rise in first half revenue on increased client usage of its products and said that its research & development subsidiary is expected to be self-funded by the end 2020.

Shares in the clinical-stage cell-based therapies & life sciences firm were trading 5.7% higher at 233.52 pence each on Wednesday afternoon in London.

MaxCyte licences out its technology to life sciences companies that use its cell engineering know-how in drug development.

The company expects to post revenue of USD10.9 million for the six months to the end of June, up 30% year-on-year. The rise in revenue was attributed to increased adoption and usage of the company's products by its client base.

MaxCyte highlighted that its R&D business, CARMA Cell Therapies, is now established as a wholly-owned subsidiary to facilitate independent investment and new partnerships.

Scientists working for CARMA are currently developing MCY-M11, which is a potential therapy for ovarian cancer and peritoneal mesothelioma, the company said, adding that results from a Phase I study are expected in the second half of 2020.

CARMA Cell Therapies is expected to be self-funded by the end of 2020.

Looking ahead, Chief Executive Doug Doerfler said: "We are pleased to have delivered positive momentum across all aspects of our business in the first half of 2020 and into July. We were delighted to expand our cell therapy partnerships with three industry-leaders as well as the continued clinical progress of the first CARMA therapeutic candidate, MCY-M11.

"We remain mindful of the impact of the Covid-19 global pandemic and continue to work diligently to mitigate any potential restrictions and delays in our operations and to protect our team, their families, our customers and patients. We remain confident in our prospects for long-term growth fuelled by our next-generation gene-editing enabling technology and a resilient business model."

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Feb 2021 21:38

IN BRIEF: GBP40 Million MaxCyte Subscription Ahead Of Dual Listing

IN BRIEF: GBP40 Million MaxCyte Subscription Ahead Of Dual Listing

Read more
20 Jan 2021 17:40

LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%

LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%

Read more
11 Jan 2021 14:51

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

Read more
23 Dec 2020 10:36

Maxcyte Core Life Sciences Business Results To Beat Expectations

Maxcyte Core Life Sciences Business Results To Beat Expectations

Read more
23 Oct 2020 16:04

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
13 Oct 2020 14:06

UK EXECUTIVE CHANGE SUMMARY: Danakali Hires Potash Mining Vet As COO

UK EXECUTIVE CHANGE SUMMARY: Danakali Hires Potash Mining Vet As COO

Read more
21 Sep 2020 16:24

IN BRIEF: MaxCyte Interim Revenue Jumps And Loss Narrows

IN BRIEF: MaxCyte Interim Revenue Jumps And Loss Narrows

Read more
14 Sep 2020 15:44

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Sep 2020 14:28

MaxCyte Hires Murphy As Finance Chief; Holtz Becomes Accounting Boss

MaxCyte Hires Murphy As Finance Chief; Holtz Becomes Accounting Boss

Read more
9 Sep 2020 09:35

MaxCyte appoints Amanda Murphy as CFO

(Sharecast News) - Life sciences company MaxCyte named Amanda Murphy as its chief financial officer on Wednesday, succeeding long-time CFO Ron Holtz.

Read more
18 Aug 2020 20:04

IN BRIEF: MaxCyte Says CARMA's Phase 1 MCY-M11 Trial Expanded

IN BRIEF: MaxCyte Says CARMA's Phase 1 MCY-M11 Trial Expanded

Read more
8 Jul 2020 15:51

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

Read more
7 May 2020 17:30

UK TRADING UPDATE SUMMARY: Filta Launches Covid-19 Sanitising Service

UK TRADING UPDATE SUMMARY: Filta Launches Covid-19 Sanitising Service

Read more
1 May 2020 08:54

MaxCyte Raises GBP25 Million To Fund Investments Ahead Of US IPO

MaxCyte Raises GBP25 Million To Fund Investments Ahead Of US IPO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.